Profilo
Sheldon L.
Koenig is the founder of Nuvig Therapeutics, Inc. Mr. Koenig is President & Chief Executive Officer at Esperion Therapeutics, Inc. since 2026.
Formerly, Mr. Koenig was Vice President at Merck & Co., Inc. from 2009 to 2015.
Mr. Koenig was Chief Commercial Officer & Executive VP at Portola Pharmaceuticals LLC from 2019 to 2020.
Mr. Koenig was Senior VP & Head-Cardiovascular Franchise at Sanofi Corp.
Education includes an undergraduate degree from Drexel University and an MBA from Monmouth University.
Posizioni attive di Sheldon Koenig
| Società | Posizione | Inizio |
|---|---|---|
| ESPERION THERAPEUTICS, INC. | Amministratore Delegato | 18/05/2021 |
Precedenti posizioni note di Sheldon Koenig
| Società | Posizione | Fine |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2020 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2015 |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Fondatore | - |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Corporate Officer/Principal | - |
Formazione di Sheldon Koenig
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers biopharmaceutical products | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
Drexel University
Drexel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monmouth University
Monmouth University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Health Technology |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Health Technology |
















